Making a Major Impact on B Cell Cancers
source: shutterstock.com

Making a Major Impact on B Cell Cancers

  Accutar Biotechnology, Cranbury, New Jersey recently announced via BioSpace that dosing has begun with the first patient enrolled in the Phase 1 trial of AC0676 a chimeric degrader molecule…

Continue Reading Making a Major Impact on B Cell Cancers
This Company Just Withdrew Two of Its Drug Approvals for Mantle Cell Lymphoma and Marginal Zone Lymphoma
source: shutterstock.com

This Company Just Withdrew Two of Its Drug Approvals for Mantle Cell Lymphoma and Marginal Zone Lymphoma

According to a story from BioPharma Dive, the drug company AbbVie has recently announced its decision to withdraw two different approvals for its cancer therapy Imbruvica. The approvals were withdrawn…

Continue Reading This Company Just Withdrew Two of Its Drug Approvals for Mantle Cell Lymphoma and Marginal Zone Lymphoma
Possible Treatment for Rare Lymphomas Withdrawn from FDA Consideration
source: pixabay.com

Possible Treatment for Rare Lymphomas Withdrawn from FDA Consideration

According to a story from AJMC, the drug developer Incyte has made the decision to withdraw its New Drug Application (NDA) for its investigational therapy parsaclisib. This therapy was submitted…

Continue Reading Possible Treatment for Rare Lymphomas Withdrawn from FDA Consideration
NDA Withdrawn for Parsaclisib for MCL, MZL, Follicular Lymphoma
Source: Pixabay

NDA Withdrawn for Parsaclisib for MCL, MZL, Follicular Lymphoma

Incyte has withdrawn its New Drug Application (NDA) for parsaclisib, which is an investigational treatment for various types of lymphoma, including relapsed/refractory mantle cell lymphoma (MCL), follicular lymphoma, and marginal…

Continue Reading NDA Withdrawn for Parsaclisib for MCL, MZL, Follicular Lymphoma
FDA Accepts NDA For Parsaclisib for Non-Hodgkin Lymphoma
source: pixabay.com

FDA Accepts NDA For Parsaclisib for Non-Hodgkin Lymphoma

The FDA will review parsaclisib as a treatment for Non-Hodgkin lymphoma (NHL) after accepting Incyte's New Drug Application (NDA). Specifically, the NDA was submitted for the treatment of relapsed or…

Continue Reading FDA Accepts NDA For Parsaclisib for Non-Hodgkin Lymphoma
BRUKINSA for MCL Approved in Russia
Source: https://unsplash.com/photos/ZHys6xN7sUE

BRUKINSA for MCL Approved in Russia

BRUKINSA (zanubrutinib), an orally administered Bruton's tyrosine kinase (BTK) inhibitor, has been approved in various countries for the treatment of mantle cell lymphoma (MCL), Waldenström's macroglobulinemia, and marginal zone lymphoma. For…

Continue Reading BRUKINSA for MCL Approved in Russia
Treatment Options in Relapsed/Refractory Mantle Cell Lymphoma: Different Factors to Consider
source: pixabay.com

Treatment Options in Relapsed/Refractory Mantle Cell Lymphoma: Different Factors to Consider

In a video posted on OncLive, Dr. Anita Kumar, a medical oncologist, discusses different considerations that must come into play when choosing a treatment for people living with relapsed/refractory mantle…

Continue Reading Treatment Options in Relapsed/Refractory Mantle Cell Lymphoma: Different Factors to Consider
Experimental CAR T-Cell Therapy for Mantle Cell Lymphoma May Soon Get EU Approval
source: pixabay.com

Experimental CAR T-Cell Therapy for Mantle Cell Lymphoma May Soon Get EU Approval

According to a story from BioSpace, the biopharmaceutical company Kite announced recently that the Committee for Medicinal Products for Human Use (CHMP), part of the European Medicines Agency, has released…

Continue Reading Experimental CAR T-Cell Therapy for Mantle Cell Lymphoma May Soon Get EU Approval
This New Treatment for Mantle Cell Lymphoma has the Potential for Durable Remissions
source: pixabay.com

This New Treatment for Mantle Cell Lymphoma has the Potential for Durable Remissions

  A recent article in The American Journal of Managed Care (AJMC) heralds the approval of a third CAR T-cell therapy, called Tecartus. Kite Pharma’s cell-based gene therapy is the first…

Continue Reading This New Treatment for Mantle Cell Lymphoma has the Potential for Durable Remissions